Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol
Prostate cancer detection percentages of repeat biopsy in patients with positive multiparametric magnetic resonance imaging (prostate imaging reporting and data system/likert 3–5) and negative initial biopsy. A mini systematic review
Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Predicting the need for biopsy to detect clinically significant prostate cancer in patients with a magnetic resonance imaging–detected prostate imaging reporting and data system/Likert ≥3 Lesion: Development and multinational external validation of the imperial rapid access to prostate imaging and diagnosis risk score
Local failure events in prostate cancer treated with radiotherapy: A pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)
Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Results of a planned interim analysis of a prospective phase 2 study